Search

AX200

The expression of the endogenous AX200 protein in the brain is increased after brain damage. … Thus, if this drug administered in the acute phase of stroke, the brain’s own protective action is supported.

AVN-944

AVN944 is a biotech drug that demonstrated a statistically meaningful impact on IMPDH and other proteins that are critical to activities in cancer cells, including nucleotide biosynthesis, energy and metabolism … AVN944 has been associated with cancer cell death in clinical trials. It is being investigated for the treatment of patients with advanced hematologic malignancies.

Larazotide

An octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.

ARG098

ARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.

Laquinimod

It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. … Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries.

Canfosfamide

Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.

VLTS-589

VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.

Zatebradine

The usage of the INN stem '-bradine' in the name indicates that Zatebradine is a bradycardic agent. Zatebradine has a monoisotopic molecular weight of 456.26 Da.

Paliroden

It is indicated for use in Alzheimer's Disease and Parkinson’s. … Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines.

Methyl red